1 results match your criteria: "Dept. of Internal Medic University Hospital of Cologne[Affiliation]"
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Haematologica
February 2021
University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Article Synopsis
- The study explores a new treatment approach for chronic lymphocytic leukemia (CLL) combining bendamustine debulking followed by ofatumumab and ibrutinib, targeting patients with higher tumor loads.
- Out of 65 analyzed patients, 92% showed a response to the treatment, with 14% achieving minimal residual disease negativity, indicating a significant reduction of cancer cells.
- The treatment was generally well-tolerated with common side effects being manageable, and the ongoing maintenance aims to improve outcomes, although ibrutinib remains effective as a standalone therapy in non-trial settings.